UCB gets FDA approval for Bimzelx for hidradenitis suppurativa
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2024
0mins
FDA Approval for Bimzelx: UCB has received FDA approval for its drug Bimzelx, making it the first IL-17A and IL-17F inhibitor approved for moderate-to-severe hidradenitis suppurativa (HS).
Additional Approvals: Bimzelx is also approved for other conditions including plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
